Evidence map›Paper›PMID 40310530›Full record

ReviewNaunyn-Schmiedeberg's archives of pharmacology2025

Inflammasomes and autophagy in cancer: unlocking targeted therapies.

Jitendra Gupta, Mohammed Hashim Mohammed, Tawfeeq Alghazali, Subasini Uthirapathy, Roopashree R, Vishal Thakur, Manpreet Kaur, K Satyam Naidu, Aziz Kubaev, Mahmoud Mussleh Al-Mukhtar

Abstract readReview
PubMed Publisher
In one paragraph

Review in Naunyn-Schmiedeberg's archives of pharmacology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Autophagy in Melanoma: Molecular Mechanisms and Therapeutic Perspectives.International journal of molecular sciences · 2026
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Jitendra GuptaInstitute of Pharmaceutical Research, GLA University, Mathura, Pin Code 281406, U.P., India. smartjitu79@gmail.com.
Mohammed Hashim MohammedMedical Laboratory Techniques Department, College of Health and Medical Technology, Al-Maarif University, Anbar, Iraq. dr.m.h.mohammed@gmail.com.
Tawfeeq AlghazaliThe Islamic University of Najaf, Najaf, Iraq.
Subasini UthirapathyPharmacy Department, Tishk International University, Erbil, Kurdistan Region, Iraq.
Roopashree RDepartment of Chemistry and Biochemistry, School of Sciences, JAIN (Deemed to be University), Bangalore, Karnataka, India.
Vishal ThakurCentre for Research Impact & Outcome, Chitkara University Institute of Engineering and Technology, Chitkara University, Rajpura, 140401, Punjab, India.
Manpreet KaurDepartment of Pharmacy, Chandigarh Pharmacy College, Chandigarh Group of Colleges-Jhanjeri, Mohali, 140307, Punjab, India.
K Satyam NaiduDepartment of Chemistry, Raghu Engineering College, Visakhapatnam, Andhra, Pradesh- 531162, India.
Aziz KubaevDepartment of Maxillofacial Surgery, Samarkand State Medical University, 18 Amir Temur Street, 140100, Samarkand, Uzbekistan.
Mahmoud Mussleh Al-MukhtarAnesthesia Techniques Department, College of Health and Medical Techniques, Al-Mustaqbal University, 51001, Babylon, Iraq.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

This study clarifies the interaction between autophagy and inflammasome within the cancer framework. The inflammasome generates pro-inflammatory cytokines to direct the immune response to pathogens and cellular stressors. Autophagy maintains cellular homeostasis and can either promote or inhibit cancer. These pathways interact to affect tumorigenesis, immune responses, and therapy. Autophagy controls inflammasome activity by affecting cancer pathogenesis and tumor microenvironment inflammation, highlighting novel cancer therapeutic approaches. Recent studies indicate that modulating autophagy and inflammasome pathways can boost anti-cancer immunity, reduce drug-resistance, and improve therapeutic efficacy. Recent studies indicate modulating inflammasome and autophagy pathways can augment anti-cancer immunity, mitigate therapy resistance, and improve treatment efficacy. Cancer research relies on understanding the inflammasome-autophagy relationship to develop targeted therapies that enhance anti-tumor efficacy and reduce inflammatory symptoms. Customized therapies may improve outcomes based on autophagy gene variations and inflammasome polymorphisms. This study investigates autophagy pathways and the inflammasome in tumor immunopathogenesis, cytokine function, and cancer therapeutic strategies, highlighting their significance in cancer biology and treatment.

Indexed as

Antineoplastic AgentsAutophagyInflammasomesNeoplasmsAnimalsHumansMolecular Targeted TherapyTumor MicroenvironmentAntineoplastic AgentsInflammasomesAutophagyCancerCytokinesInflammasomeTreatment

Identifiers

PMID40310530

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.